The Colgan Lab studies mucosal inflammation with focus on intestinal inflammation in the context of inflammatory bowel disease and other GI diseases. Studies are aimed at understanding how epithelial and endothelial cells coordinate barrier function and inflammatory responses at mucosal surfaces. Our lab takes a multifaceted approach by investigating the relationships between gut microbiota, host immune system, genetic background, and environmental influences as it pertains to mucosal health and disease, with research emphasis on energy metabolism, host-microbe interactions, hypoxia-inducible factor, and innate immunity.
Click here for a complete list of published work in Dr. Colgan's Bibliography.
Sean Colgan, Ph.D
Levine-Kern Professor of Medicine and Immunology
A common, but often underappreciated feature of tissue inflammation is the acidification of the inflammatory microenvironment. My research is focused on furthering our understanding of the mechanisms and impact of inflammatory acidosis in the context of inflammatory bowel disease. In our recent research, we have demonstrated that neutrophil transmigration results in significant acidification of the extracellular space and that intestinal epithelial cells cope with this inflammatory acidification through the upregulation of SLC26A3, which promotes pH homeostasis. We are currently actively researching the mechanisms involved in inflammatory acidification and the impact is has on both intestinal epithelial cell function and the microbiota.
Notable Press on Ian’s work:
Ian Cartwright, Ph.D https://www.eurekalert.org/pub_releases/2021-05/ru-eoc051421.php
Postdoctoral Fellow https://www.nsf.gov/news/mmg/mmg_disp.jsp?med_id=187337&from=search_list
In the Colgan Lab, I research the interaction between autophagy, the intestinal epithelium, and the gut microbiota. Previous genome-wide association studies have revealed that polymorphisms in autophagy genes confer increased susceptibility to inflammatory bowel disease (Crohn's Disease and ulcerative colitis), and that this increased susceptibility is due in part to defects in intestinal epithelial homeostasis. In addition, the gut microbiota and microbiota-derived metabolites have been shown to positively regulate the intestinal epithelium and to protect against intestinal inflammation. My work focuses on better understanding these interactions so as to leverage this knowledge in the development of more effective treatments for inflammatory bowel disease.
Alexander Dowdell, Ph.D
Metabolites across multiple classes are involved in a complex, chemically-mediated crosstalk between the gut microbiota and host tissues. In the Colgan Laboratory I am working to delineate the role of gut microbial and host-derived small molecules in microbiota-host interactions and mucosal innate immunity in health and disease. In this we work to identify new bioactive microbiota-derived compounds and determine their contribution to intestinal homeostasis. In clarifying dysbiotic and inflammatory-induced shifts from intestinal homeostasis we hope to not only further understand the metabolism of disease, but also identify new and innovative therapies for IBD.
J Scott Lee, Ph.D
We are working on the design and chemical synthesis of novel proteolysis targeting chimeras (PROTACs) for protein of interest selective degradation. Various PROTACs have been tested in vitro to monitor the degradation of our proteins of interest and their downstream effects. We are investigating potential therapeutic candidates for inflammatory bowel disease through selective protein degradation.
Alfredo Ornelas Sanchez, Ph.D
Bacterial metabolism is a key determinant of antibiotic lethality. As metabolism slows, energetically demanding processes targeted by many antibiotics also decrease in activity, allowing bacteria to remain viable in the presence of antibiotics. This antibiotic tolerance promotes treatment-refractory infections and the evolution of heritable antibiotic resistance. Our work focuses on understanding and enhancing bacterial metabolism to improve antibiotic killing.
MD, Ph.D Candidate
Creatine metabolism has a vital role in the cellular energetics of many tissues. In the intestine, it has been shown that proper creatine transport is important for maintaining intestinal barrier function, and that parts of the creatine pathway may be dysregulated in inflammatory bowel disease. My work focuses on understanding the role and regulation of creatine kinase in the intestinal epithelium.
Geetha Bhagavatula, MD
The Hall lab works in close collaboration with the Colgan Lab due to our similar research focuses. As a pediatric gastroenterologist, I am interested in the role of intestinal barrier and the mucosal environment on human disease. We have focused on the function of the creatine transporter, a key regulator of energetics within the cell. We have found that the creatine transporter is vital to intestinal epithelial barrier function and dysregulated in inflammatory bowel disease. We continue to use a variety of in vitro and in vivo techniques to investigate the basic mechanism of epithelial function as well as working on translational research studies.
Caroline Hall, MD, Ph.D
The Kao lab is focused on the impact of purines on cell metabolism in the context of host-microbe interactions, primarily at mucosal surfaces. The lab also investigates the role of purines on bacterial stress responses and how changes in bacterial metabolism influence bacterial susceptibility to antibiotics.
Daniel Kao, MD, Ph.D.
We are interested in examining the interplay between the innate immune system and heme regulated pathways in the GI tract, especially as it pertains to inflammatory bowel disease.
Joseph Oniyah, MD
The Steiner lab works in close collaboration with the Colgan Lab due to our similar research focuses. As a gastroenterologist and inflammatory bowel disease (IBD) specialist, I am interested in understanding the cellular and molecular mechanisms of inflammation and fibrosis in IBD. We utilize many approaches to investigate these mechanisms both in vitro and in vivo. The ultimate end goal is to discover targets and develop new medical therapies for IBD patients.
Calen Steiner, MD, MS
Rosemary Callahan Toma Evanoff Camila Hanson
Professional Research Assistant Professional Research Assistant Professional Research Assistant
Joseph Oniyah Lab Calen Steiner Lab Ian Cartwright Lab
Rachael Kostelecky Emily Murphy Nichole Welch
Professional Research Assistant Professional Research Assistant Senior Professional Research Assistant
Sean Colgan Lab Caroline Hall Lab Sean Colgan Lab
Colgan Lab Contact:
12700 E.19th Ave. B146
Research Complex 2
Aurora, CO 80045
Lab: (720) 724-7249